JENNA CORRAL: Open Payments
NPI 1184236556 · HOUSTON, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$785 in 38 payments from 10 companies in 2025. Trend: 2023 $19 · 2024 $1,160 · 2025 $785
Food & beverage: $747Education: $39
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 13 | $168 |
| Janssen Pharmaceuticals, Inc | 4 | $150 |
| Neurocrine BioSciences, Inc. | 5 | $134 |
| Otsuka America Pharmaceutical, Inc. | 4 | $88 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 4 | $82 |
| Vanda Pharmaceuticals Inc. | 3 | $62 |
| E.R. Squibb & Sons, L.L.C. | 2 | $42 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $21 |
| Supernus Pharmaceuticals, Inc. | 1 | $20 |
| Axsome Therapeutics, Inc. | 1 | $19 |
Products named: VRAYLAR, INGREZZA, INVEGA SUSTENNA, CAPLYTA, REXULTI, FANAPT, COBENFY, INVEGA.
Industry payments across TX — which companies pay providers there.
